Oncology Research

Hera BioLabs Announces Exclusive Global License with Charles River

Hera BioLabs Announces Exclusive Global License with Charles River

Charles River will license Hera’s SRG rat (OncoRat), the first [...]

Hera Admin2022-03-16T17:22:17+00:00

Rapid Creation of Bioluminescent Cell Lines for Orthotopic and Metastatic Rodent Oncology Studies

In vivo chronic disease research (IVCDR), IVO, CLE, Precision Toxicology and Efficacy News

Rapid Creation of Bioluminescent Cell Lines for Orthotopic and Metastatic Rodent Oncology Studies

The piggyBac (PB) transposon system delivers highly stable transgenes without [...]

Hera Admin2022-02-25T21:54:50+00:00

The SRG OncoRat for Precision Cancer Medicine

Hera Admin2023-03-01T07:25:24+00:00

In Vivo Targeting Of Mutant KRAS Using Human Cancer Xenografts In The Immunodeficient SRG OncoRat®

Oncology Research

In Vivo Targeting Of Mutant KRAS Using Human Cancer Xenografts In The Immunodeficient SRG OncoRat®

Targeting KRAS In Oncology Research? KRAS has become an important [...]

Jack Crawford2022-06-01T13:49:35+00:00

Hera’s Poster For American Association for Cancer Research (AACR) Annual Meeting 2021

Jack Crawford2021-04-09T21:55:31+00:00

Local Injection of Submicron Particle Docetaxel is Associated with Tumor Eradication, Reduced Systemic Toxicity and an Immunologic Response in Uro-Oncologic Xenografts. Maulhardt et al

Jack Crawford2021-03-24T17:53:42+00:00

Orally -Bioavailable Androgen Receptor Degrader, Potential Next-Generation Therapeutic for Enzalutamide-Resistant Prostate Cancer. Ponnusamy and Narayana et al

Jack Crawford2021-04-05T09:15:41+00:00

A 2019 Clinical Cancer Research Paper Review: Improving Preclinical Anticancer Studies Using Rat Xenograft Model Systems

Jack Crawford2022-10-07T08:35:25+00:00

HeraBioLabs | Ramesh Narayanan

Jack Crawford2023-03-01T07:26:07+00:00

HeraBioLabs | Goutham Narla

Jack Crawford2023-03-01T07:25:50+00:00

Previous 678 Next

Title